Notícias

Eli Lilly (NYSE:LLY) has agreed to acquire Engage Biologics in a deal worth up to $202 million. Engage Biologics is developing Tethosome, a non-viral DNA delivery platform for genetic medicines. This transaction is Lilly’s seventh acquisition of 2026 and is intended to expand its genetic medicines capabilities. Eli Lilly comes into this deal with strong recent stock performance, with the share price at $1,041.65 and up 15.4% over the past 30 days and 3.5% over the past week. Over the past...

A suite of new studies suggest drugs such as Ozempic and Zepbound might slow tumor progression and improve survival, but more research is needed to confirm the findings.

Late-stage trial data strengthens Lilly's obesity drug pipeline.

Retatrutide helped patients lose up to 28.3% of body weight over 80 weeks.

Eli Lilly and Company (NYSE:LLY), featuring a net income margin of 34.99% and upside potential of 20.64%, secures a spot on our list of the best extremely profitable stocks to buy according to Wall Street analysts. The company reported net income of $20.64 billion for the recently completed fiscal year (FY25). That earnings strength was […]

Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.

GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.

LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.

Eli Lilly’s investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.

Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.

The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome

Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.

Eli Lilly (LLY) said Thursday its investigational triple hormone receptor agonist retatrutide delive

Wall Street has rediscovered the stock-split playbook. KLA (NASDAQ: KLAC) announced a 10-for-1 forward stock split in May 2026 alongside a fiscal Q3 earnings beat and a roughly 21% dividend hike, with the stock trading in the $1,800 range. Earlier in the year, Booking Holdings (NASDAQ: BKNG) completed a 25-for-1 split announced in February 2026, taking ... Will ASML, Lilly, or TransDigm Be the Next Big Stock Split?

Eli Lilly (NYSE:LLY) shares gained around 2% in premarket trading on Thursday after the company released positive late-stage clinical trial results for its experimental obesity treatment retatrutide. The study showed that patients diagnosed with obesity lost an average of 28.

Demand for weight loss drugs may fuel growth for more than one player.

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO David Ricks told investors “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue ... Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.

An investigational drug developed by Eli Lilly delivered clinically meaningful weight loss in a trial, the company said as it looks expand its obesity treatment portfolio amid soaring demand.

The healthcare team covers Q1 results from pharma and medtech companies and provides a wrap-up of the key takeaways.

LONDON/NEW YORK, May 21 (Reuters) - Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U. Prices for the lowest doses of both Novo's oral Wegovy and Lilly's Foundayo tend to be lower than for their injected obesity ‌medicines, and at par with those offered by pharmacies that mix the ingredients themselves and make compounded versions.

The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Elon Musk could pass an unthinkable wealth threshold, becoming the world’s first trillionaire, depending on investors’ excitement for SpaceX shares when it goes public. If the company surpasses a valuation of about $1.7 trillion, then Musk’s slightly more than 40% stake, combined with his Tesla shares, would make him the first man with a net worth eclipsing 13 figures. The calculation omits restricted shares that SpaceX has granted to Musk, but which haven’t been earned, though it includes options he could exercise shortly.

Novo Nordisk-linked pharmaceutical strength helped Denmark post a fourth straight quarter of economic expansion.

Eli Lilly (NYSE:LLY) has partnered with Collaborative Drug Discovery to make its AI drug discovery platform, Lilly TuneLab, more widely accessible. Biotech companies using CDD Vault can now access Lilly's predictive AI and machine learning tools directly in their existing research workflows. The agreement is designed to support broader data sharing and collaboration across drug discovery partners. Eli Lilly enters this partnership with strong recent stock performance and a high share price...

These stocks have declined this year, while the consensus estimates for the companies’ earnings per share have soared.

Bristol Myers Squibb said on Wednesday it is partnering with Anthropic ‌to make its Claude AI model ‌available to over 30,000 employees in an effort to ​accelerate the discovery, development and delivery of new medicines. • Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its ‌use in research, ⁠drug development, manufacturing and other commercial and medical affairs. • Agentic ​AI, which ​requires little human intervention, could increase clinical development productivity by about 35% to 45% ​over the ‌next five years, consultancy McKinsey said last ​year.

(Bloomberg) -- The way Unilever Plc Chief Executive Officer Fernando Fernandez starts every meeting at the consumer products maker says a lot about the mindset of corporate bosses who fear their companies have lost their edge.Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensTrump Thre

On a recent episode of Earn Your Leisure titled “The #1 Investing Mistake Keeping You Broke,” co-host E delivered a blunt diagnosis for retail investors: stop trading the stocks you should be holding. “The ones that are leading now will lead,” he said, warning that top companies could compound 4,000% or 5,000% over five or ... “4,000% or 5,000% Over Five or Six Years”: Why Patient Investors in NVDA, AMD, and LLY Are Winning